Suven Life Sciences Ltd$.$ Reported earnings per share of Rs$.1\mathrm{.}50$ in $2023$ and paid dividends per share of Rs$.0\mathrm{.}42$ in $2023.$ The firm also reported the following

Net Income Rs$.30$ million

Interest Expense Rs$.0\mathrm{.}8$ million

Book Value of Debt Rs$.7\mathrm{.}6$ million

Book Value of Equity Rs$.160$ million

The firm faced a corporate tax rate of $38\mathrm{.}5\%($The market value debt to equity ratio is $5\%).$ The Treasury bond rate is $7\%$ and market premium is $5\mathrm{.}5\%.$ The firm expected to maintain these financial fundamentals from $2024$ to $2028.$ After which it was expected to become a stable firm with an earnings growth rate of $6\%.$ The Firms financial charactartics were expected to approach industry averages after $2028$

The industry averages were as follows

Return of capital $12\mathrm{.}5\%$

Debt$/$Equity ratio $25\%$

Interest Rate on Debt $7\%$

Suven Life Sciences Ltd Had a beta of $0\mathrm{.}85$ in $2023$ and the unlevered beta was not expected to change over time

a$)$ What is the expected growth rate in earnings, based upon fundamentals, for the high growth period $2024$ to $2028?$

b$)$ What is the expected payout ratio after $2028?$

c$)$ What is the expected price beta after $2028?($Note: The unlevered beta is the beta of a company without any debt$)$

d$)$ What is the expected price at the end of $2028?$

e$)$ Calculate yearly cash flows and estimate the value of the stock, using the two$-$stage dividend discount model.

f$)$ How much of this value can be attributed to extraordinary growth and how much to the stable growth?